News
EQS-Adhoc: GN Store Nord A/S: GN moves to “one company” governance structure; appoints Peter Karlstromer to Group CEO
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
About a year ago, President Joe Biden signed the Inflation Reduction Act into law. Among the many things that law achieved was to give Medicare, for the first time, the ability to directly negotiate
Why Catalent Stock Zoomed 12% Higher This Week
Catalent (NYSE: CTLT) is one company that probably wishes the summer would never end. As August came to a close, the contract drug manufacturer's stock enjoyed a nearly 12% rise over the course of
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Why Novocure Stock Fell 24.4% This Week
Shares of Novocure (NASDAQ: NVCR) are down 25.9% so far this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence, as the company announced a
Viatris Stock: Bear vs. Bull
If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.
Generic drug
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
LivaNova präsentiert Essenz In-Line Blood Monitor mit U.S. FDA 510(k)-Zulassung und CE-Prüfzeichen
LivaNova PLC (Nasdaq: LIVN), ein Marktführer im Bereich der Medizintechnik, gab heute bekannt, dass es die 510(k)-Zulassung der US-amerikanischen Food and Drug Administration (FDA) und das
Why Insulet Stock Rocked the Market Today
Medical device maker Insulet's (NASDAQ: PODD) stock was the cure for the investor blues on Wednesday. Following news of a large insider buy, the shares subsequently shot more than 6% higher on the
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz™ In-Line
The Top Healthcare Stocks to Buy With $100
Investing in stocks isn't just for the rich and famous since quality stocks can be found at almost any price. Some are trading for well above $1,000 per share, while others go for less than $100
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Why Catalent Stock Surged Nearly 5% Higher Today
Contract drug manufacturer Catalent (NYSE: CTLT) provided some very effective medicine to its investors on Tuesday. The company's shares leaped almost 5% higher following the publication of its
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
When Joe Biden ran for president in 2020, he promised to allow Medicare to negotiate directly with pharmaceutical companies. Last year, he signed the Inflation Reduction Act into law and achieved
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: SARTORIUS AG: S&P Global Ratings assigns investment grade rating to Sartorius
EQS-News: Evotec SE reports results for the first half-year 2023 and provides corporate updates
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Why Premier Stock Fell 16% This Week
Shares of Premier (NASDAQ: PINC) are down 15.5% this week as of 12:05 p.m. ET Friday, according to data provided by S&P Global Market Intelligence, after the healthcare-improvement leader announced
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics Plc
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS).
Both companies offer
Why Invitae Stock Is Crashing Today
Shares of Invitae (NYSE: NVTA) were crashing 19.4% lower as of 12:13 p.m. ET on Thursday. The decline came on the heels of two developments.
Invitae revealed in a regulatory filing on Wednesday that
2 No-Brainer Biotech Stocks to Buy Right Now
Following the market's gloomy 2022, this year has been a breath of fresh air with the S&P 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic